Federated Hermes, Inc. Cullinan Oncology, Inc. Transaction History
Federated Hermes, Inc.
- $43 Billion
- Q4 2024
A detailed history of Federated Hermes, Inc. transactions in Cullinan Oncology, Inc. stock. As of the latest transaction made, Federated Hermes, Inc. holds 3,802 shares of CGEM stock, worth $33,419. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3,802
Previous 2,277
66.97%
Holding current value
$33,419
Previous $38,000
21.05%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding CGEM
# of Institutions
153Shares Held
67.1MCall Options Held
41.1KPut Options Held
112K-
Bio Impact Capital LLC Cambridge, MA7.65MShares$67.2 Million13.93% of portfolio
-
Bvf Inc San Francisco, CA5.75MShares$50.5 Million2.62% of portfolio
-
Black Rock Inc. New York, NY3.55MShares$31.2 Million0.0% of portfolio
-
Chi Advisors LLC New York, NY3.41MShares$30 Million15.23% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.38MShares$29.7 Million1.02% of portfolio
About Cullinan Oncology, Inc.
- Ticker CGEM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,612,200
- Market Cap $401M
- Description
- Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with ...